Phosphate binder use is associated with a 25% and 37% decreased risk of death from infection-related causes and all-causes, respectively, compared with non-users.
Achieving a phosphate value of 1.4 mmol/L seemed optimal.
Intravenous iron and erythropoietin produced a similar hemoglobin response among hemodialysis patients with moderate anemia.
The group targeting higher hemoglobin values experienced less decline in graft function.
Secondary hyperparathyroidism may have a detrimental effect on successful arteriovenous fistula creation, researcher says.
From 2004 to 2012, the incidence of AKI increased from 4.9% to 14.2% among CABG patients and from 2.7% to 8.8% among PCI patients.
HD patients with untreated or ineffectively treated anemia prior to dialysis initiation were more likely to die than those who had consistently well-treated anemia.
In a phase 3 trial, acute kidney injury developed in 13.2% of patients undergoing invasive coronary angiography compared with 5.6% of those undergoing computed tomography angiography.
Patients with autosomal dominant polycystic kidney disease treated with tolvaptan experienced a 35% decrease in the annual rate of decline in eGFR.
The 5-year survival rates was 80.7% for patients in the lowest quartile of serum uric acid at HD initiation versus 89.6% for those in the highest quartile.
Kidney Week 2017 Videos
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)